David joined Metadeq as CEO in January 2023 to lead the company to commercialization stage. Prior, David was CEO of AltheaDx, Inc., a San Diego-based diagnostics company focused on pharmaco-genomics (PGx) in depression & anxiety. He joined the company in December 2018, first as Interim CEO and then continuing to permanent CEO in January 2020. He had served on the Board of Directors since December 2015 as a representative of Ally Bridge Group, where he led the investment for a syndicate of investors. At AltheaDx, David orchestrated a corporate restructuring, successfully gained Medicare Coverage and re-launched the company’s lead test kit, IDgenetix. In April 2022, Castle Biosciences (NASDAQ: CSTL) completed an acquisition for AltheaDx for a total consideration of $140 million. David remained with Castle Biosciences until August 2022 to assist with the transition and integration.

Prior to AltheaDx, David was a de facto Partner and Managing Director at Ally Bridge Group (ABG), a Hong Kong based investment fund focused on Healthcare investing. During his 5+ years, David was responsible for the biotherapeutic investments and portfolio, and played an integral role in the growth of the Fund. David sourced, led, managed and served on the boards of numerous biopharmaceutical portfolio companies. In addition to his experience investing in private companies at ABG, David has more than 15 years of experience in capital equity markets with the majority of time spent on public biotechnology and healthcare companies. He began his Wall Street career in 2001 with long/short analyst and portfolio management roles in New York City at Orbitex Management, Blumberg Capital and BNP Paribas, as well as at Exane Asset Management, in Paris. Since mid-2018, David has served as a Consulting VP of US Operations for Inventiva Pharma, SA, a France-based biotechnology company focused on MASH therapeutics, and was integrally involved in their US IPO listing in July 2020; this consultancy is under the umbrella of Sapidus Partners, LLC, a consulting company he founded in 2014.

David holds undergraduate degrees in chemistry, and English language and literature from the University of Virginia, and a Ph.D. in biochemistry and molecular biology from Georgetown University. He conducted basic science research at the National Institutes of Health for 3 years and also was a patent examiner at the United States Patent and Trademark Office in Washington, D.C. He resides in Orlando, Florida with his wife and two children and maintains family roots with a home in Chevy Chase, MD.

Prior BOD experience includes: Tunitas Therapeutics, Inc. (Director and member of the compensation committee), AltheaDx, Inc., Alzheon, Inc. (Director and head of audit committee), Neuroverse, Inc., Cold Genesys, Inc. (now CG Oncology, Inc.), 3-V Biosciences, Inc. (now Sagimet Biosciences, Inc.), Atea Pharmaceuticals, Inc. (de facto Director), Immungene, Inc. (de facto Director).

Tom has extensive process mapping and business process improvement skills, along with a solid information technology background that includes management and implementation experiences ranging from custom application design to enterprise-wide system deployment.

Tom also has hands-on experience in integrating acquisitions and in new facility startups. In working with manufacturing organizations, Tom has overseen plant automation, reporting and bar code tracking implementations. He also has broad legal experience in intellectual property (IP), contract and employment law. From January 2004 to January 2018, Tom served as ChromaDex Inc (CDXC) Chief Financial Officer. He also served as a director from March 2006 until May 2010.

Tom was responsible for overseeing all of Company’s operations, including all aspects of accounting, information technology, inventory, distribution, legal, and human resources management. From April 2015 to May 2019 , Tom served on the board of directors of MabVax Therapeutics Holdings, Inc. (OTCQB:MBVX), where he was a member of the audit, compensation and nominating and governance committees. Tom holds a B.S. in Accounting from University of Illinois, Urbana-Champaign and has been certified as a Certified Public Accountant.

Daniel is a pharmaceutical leader with over 20 years of brand and portfolio strategic marketing, management and commercial leadership roles, across: hepatology/liver disease, NASH, diagnostics, oncology, infectious diseases, cardiology, diabetes, HIV, cell/gene therapy.

The last 12 years have focused on cross-functional and commercial planning, as well as the commercialization of brands, in multiple therapeutic areas.  Led global and regional launch, strategy and capability for over 20 brands.

Formerly, Vice President, NASH Commercial Planning at Madrigal Pharmaceuticals – led cross-functional launch planning, insights generation and market preparation for launch of resmetirom for NASH – landscape analysis, diagnostic strategy, commercial opportunity identification, scenario analysis, insights generation.

Prior, was Vice President, NASH Planning at Intercept Pharmaceuticals – developed and led International and global NASH brand strategy; all aspects of cross-functional strategy and execution for NASH. Built launch blueprint, driving market-shaping, access, policy and diagnostic collaborations and disease education initiatives, including programmes and workstreams with external thought leaders across Europe

Earlier roles include Head of Global Oncology Launch Capability at AstraZeneca (leading launch capability and programmes for global Oncology organisation, delivering 4 major global launches, including for diagnostic pathways) and Head of Europe Commercial and Global Diabetes at Bristol-Myers Squibb and AstraZeneca (led global strategic and operational planning and country plan execution for the franchise; owned promotional strategy and campaign evolution – development of brand promotional platform, architecture and messaging.

Started out commercial life as a practicing Barrister and have also spent time in management consultancy (including EVERSANA) and consulted in cell and gene therapy for private equity backed companies (Syncona, Ltd).  Based in London, UK.

Aldo is Consulting CMO for Metadeq, while continuing to serve full-time as Executive Medical Director at Advanza Pharma, with a focus on Hepatology and Speciality Medicines. He is responsible for the strategy and implementation of pre-launch medical activities, including development and support of medical regulatory and R&D activities for new therapies for patients with MASH, liver fibrosis & cirrhosis. Specific job duties include: clinical trial implementation and execution, running educational programmes, Advisory Boards, KOL and scientific society collaboration and engagement, and delivering scientific publications.

Aldo has a passion for hepatology, gastroenterology and virology; he previously worked in Novartis headquarters as Senior Global Medical Director in a range of different disease areas including Hepatitis, Liver Transplant, Cell & Gene Therapies for 8 years. Prior to that he worked in medical leadership roles at Gilead and Roche.

Aldo completed his training in Internal Medicine and Hepato-Gastroenterology in France. He worked as Consultant in the Immunology Clinical Department at the Academic European Georges Pompidou Hospital in Paris until 2009, as well as several other hospitals as an affiliate physician. He holds a French board qualification in internal medicine, a post-doc in imaging techniques, a post-doc in nutrition and a post-doc in AIDS and retroviruses. He has contributed to more than 80 public & pharmaceutical company clinical trials. He more than 90 publications in the fields of liver, immunology, treatment of viral hepatitis & liver transplantation. He joined EASL in 1987.

Aldo is fluent in English, French and Spanish. He is interested in reimagining medicine, transforming science and improving health outcomes for patients.

Katrien brings over three decades of experience to the forefront of clinical research, embodying a profound commitment to clinical excellence, operational leadership, and quality assurance in the pharmaceutical industry. 

During her recent eight-year tenure at Intercept Pharmaceuticals (2017-2023), where she served as Senior Director of Clinical Operations, Katrien was instrumental in leading Clinical Operations for critical clinical trials in NASH, PBC, and BA. Her role was pivotal in the development and enhancement of the Clinical Operations department, substantially expanding its capabilities. 

As a vital member of both the Global Leadership Team and the Global Program Teams, she managed cross-functional international teams and oversaw substantial annual budgets exceeding $40 million. Prior to Intercept, Katrien worked at Boehringer Ingelheim Italia where she led the QA department, ensuring strict adherence to regulatory standards and GCP compliance, and spent more than 10 years as an independent consultant in the Clinical Research field. Katrien studied clinical chemistry in Gent, Belgium.

Juliane has honed her communications skills for the past 30 years with public and private life science companies.  Juliane has a long-established investor relations track record and has amassed broad experience in corporate and product communications, including branding and messaging, media relations, crisis communications, and relationship development and management.  

Today, Juliane works closely with a few select companies, including XOMA, where she leads the investor and corporate communications activities; and Metadeq, where she supports the company’s investor and corporate communications activities.  

Juliane is a trusted advisor to the founder of Dynamk Capital and its portfolio companies, particularly CellFE.  Notably, Juliane has been responsible for the communications surrounding the Warner Chilcott acquisition of Procter & Gamble’s pharmaceutical division, BioVail’s acquisition of Wellbutrin XL from Glaxo SmithKline, FDA approval of Bepreve® (bepotastine) and ARESTIN^® (minocycline hydrochloride), the repositioning of Serono as a biotechnology company and its initial public offering, and the Lescol XL (fluvastatin sodium) public relations campaign.  

Juliane’s most recent corporate position was as Director, Corporate Communications for Ventana Medical Systems, and her corporate experience includes Merck & Co., Inc., Reliant Pharmaceuticals, and Applied Biosciences Inc.

Jim advises companies on issues pertaining to product development and regulatory submissions, leveraging over 35 years of in vitro diagnostics experience. At Abbott Diagnostics, he held broad senior leadership roles in discovery research, immunoassay development and manufacturing operations. 

With a scientific background in protein chemistry and solid knowledge of cGMP and design controls, Jim has led the design and development of over 40 commercialized IVD assays, including established and novel biomarkers for infectious disease, cardiovascular, oncology and neuroscience diagnostics. He has managed a broad array of strategic research collaborations with both academic and government partners. Jim holds a Ph.D. in Chemistry from the University of South Carolina.

Lisa has 35 years of experience as an accomplished senior executive in biopharmaceuticals, where she focused on launching and commercializing innovative, specialty medicines globally, and has extensive experience in liver disease.

She is currently the Non-Executive Chair of Resolution Therapeutics Ltd (focused on engineered macrophage cell therapy for end stage liver disease), and a Non-Executive Director with: Ascendis Pharma A/S, Immedica Pharma AB and, until its recent acquisition, of Dechra Pharmaceuticals Plc. Additionally, Lisa is an Executive Partner for Syncona, an advisor for DRI Capital and a Trustee for CDA Foundation, which supports low- and middle-income countries to accelerate the elimination of viral hepatitis. Lisa also acts as an advisor to a number of other companies.

In her executive career, Lisa has served as Chief Commercial and Corporate Affairs Officer and President of International for Intercept Pharmaceuticals Inc., where she established the global commercial footprint for their orphan drug launch for Ocaliva®in primary biliary cholangitis (PBC) and, as part of the Executive Committee; she developed the strategy and organizational build for the NASH/MASH launch. During her tenure at Gilead Sciences Inc., she was VP Head Hepatitis C (HCV) launch planning ex-US; she also served as VP Head of Government Affairs International, VP Head of Northern Europe and GM UK & Ireland. Prior to Gilead, Lisa held senior leadership roles at GSK, including VP GM New Zealand and VP Head of Sales UK.

She holds a BSc (Hons) in Pharmacology from University College London and lives with her family in Cambridge.

Giorgio is an executive leader with a deep-rooted passion for healthcare innovation, a former academic, and an economist. He has co-founded several companies in the healthcare sector each of which reflects his commitment to addressing global health challenges.

Giorgio co-founded Keyron in 2016. As CEO, he led ForePass, a medical device with the potential to reverse type-2 diabetes and obesity, from conception to a working device and procedure, demonstrating impressive weight loss and the reversal of insulin resistance in preclinical studies, in both small and large animals. In 2019, Giorgio led the strategic de-merger of Keyron into two biotech companies: Metadeq, Ltd. and GHP Scientific, Ltd. Under his leadership, Metadeq developed a highly accurate non-invasive diagnostic test (HeparDx) for non-alcoholic liver diseases: MASLD, MASH, and liver fibrosis.

GHP Scientific is instead devoted to the discovery and development of effective pharmacological treatments for MASH. Giorgio also co-founded nutraceutical company Jemyll, the maker of Metabolyte, a highly metabolically efficient ingredient that is commercially available in the US. Giorgio is a trained economist with over 25 published papers in the highest ranked scientific journals on topics such as carbon taxation, market power, policy incentives, and electricity market integration, his research is widely cited and recognized by academia, industry, and governments worldwide. During his academic career, he has taught economics courses at B.Sc., M.Sc., and Ph.D. levels including more than 1,000 students.

Giorgio has served as a Principal Investigator and Senior Consultant to the UK government multiple times. His education includes a B.Sc. in Economics & Econometrics, an M.Sc. in International Finance (University of Warwick), and an ESRC-funded Ph.D. in Financial Economics & Management (Imperial College Business School).

Nicol is Metadeq’s Investor and Director of Metadeq’s Diagnostics Division. He is a Member of the Board of Directors.

He is a leading electronic engineer with an extensive technology background and is an established life sciences investor.

He serves as Divisional Chief Executive Officer of Creative Solutions Division at The Vitec Group plc. Nicol has been Senior Vice President of Technology at Vitec Videocom Ltd. since August 2013. He served as Senior Vice President of Creative Solutions, Broadcast Division at The Vitec Group plc. He served as Chief Executive Officer of Teradek. Nicol has an extensive technology background, previously working for Impac Technologies and the GE Security Digital Video Center of Excellence where he was responsible for leading all engineering activities. In 2008, he founded Teradek and grew it from a small engineering services and licensing firm into an international supplier of digital video products. He holds a degree in Electronic Engineering from the University of Pretoria, South Africa and obtained black belt certifications in Six Sigma and Lean Manufacturing during his time with GE.

Michael joined the Metadeq Board of Directors in August 2023.  He brings more than three decades of expertise both in executive and non-executive roles in sales, marketing and general management, combined with a unique cultural perspective from living in nine different countries across Europe and the Americas.  In his last role, he served as Chief Commercial Officer at miDiagnostics and has been steering the global commercial activities of the company in the Point-Of-Care (POC) arena. Prior, Michael was President and General Manager of the International Business at Metabolon with full P&L responsibility and leading the international commercial and operational activities of the company. 

Michael also was Global Head of Sales and Business Development and later as Chief Commercial Officer at Definiens AG. Earlier in his career, at Roche Diagnostics Michael was SVP of Global Marketing for Roche’s NPT (POC) business. Michael started his carrier at Bayer Diagnostics (today Siemens Diagnostics), spending twelve years in a variety of marketing and commercial roles. 

Michael has served on several boards and has held numerous roles as an Advisor for diagnostic and life science companies. Michael holds a degree in Marketing and Finance from the private Bayer University and is a certified sales coach for the Miller Heiman sales methodology.

Stephen is Chair of the Metadeq Advisory Board. He earned his medical degree from the University of Mississippi School of Medicine. He completed his internal medicine residency and gastroenterology fellowship at Brooke Army Medical Center and a 4th year advanced liver disease fellowship at Saint Louis University. 

Stephen is a Visiting Professor of Hepatology at the Radcliffe Department of Medicine, University of Oxford. He is internationally known for studies in MASLD/MASH with over 300 peer reviewed publications and an H Index of 99. He currently serves as the chairman for both Pinnacle Clinical Research and Summit Clinical Research (an internationally recognized integrated research organization with over 100 sites worldwide) in San Antonio, Texas. He is the lead PI for numerous MASH development programs.

Quentin is Professor of Experimental Hepatology and Deputy-Dean of Research & Innovation in the Faculty of Medicine, Newcastle University. A practising clinician, he is also an Honorary Consultant Hepatologist in the Liver Unit at the Freeman Hospital, Newcastle.

His translational research has extended from the bench to the bedside with particular focus on the pathogenesis, diagnosis and treatment of Non-Alcoholic Fatty Liver Disease (NAFLD), a common liver condition that is strongly associated with obesity, diabetes and other features of the metabolic syndrome. He leads a discovery-science research group at the Translational & Clinical Research Institute and is actively involved in ongoing clinical trials of new therapies and biomarkers for fatty liver disease and hepatic fibrosis.

He co-ordinates two major EU-funded research consortia: the H2020 funded EPoS (Elucidating Pathways of Steatohepatitis) consortium; and the IMI2 funded LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) consortium.

Geltrude is one of the pioneers showing that bariatric surgery induces the remission of type 2 diabetes in people with obesity, even before any meaningful weight loss. She published the first randomized controlled trial comparing the efficacy of lifestyle modification and best medical care with that of bariatric surgery in the New England Journal of Medicine and both the 5-year and 10-year follow-up in The Lancet. She demonstrated that the bypass of the duodenum and the jejunum reverses diabetes and insulin resistance and searched for their mediators.

She found that bypassing the small intestine by surgery prevents it from producing heat shock proteins, mainly glucose regulatory protein 78 (GRP78), which cause insulin resistance, resulting in improved glucose homeostasis. The Western diet causes endoplasmic reticulum (ER) overload in the epithelium of the upper gut inducing unfolded protein accumulation. This, in turn, causes the dissociation of GRP78 from the ER transmembrane receptors PERK, ATF6 and IRE1 and the secretion of GRP78 in the blood stream. In the liver GRP78 causes non-alcoholic steato-hepatitis and insulin resistance in the skeletal muscle.

She studied medicine and completed her residency in endocrinology and gastroenterology at the Catholic University & Policlinico A. Gemelli in Rome, Italy. She received her PhD in clinical pharmacology from the University of Ghent in Belgium. She returned to the Catholic University in 1994 as an assistant professor in the Division of Metabolic Diseases. She became associate professor at the same university in 2000 and is the Chief of the Division of Obesity and Related Disorders at the University Hospital Policlinico A. Gemelli. Since 2015, she also holds a part-time position as Professor of Diabetes and Nutrition at the King’s College London, UK.

Since 2018, she participates as one of the representatives of the European Association for the Study of Diabetes to issuing the guidelines for the therapy of type 2 diabetes together with the American Diabetes Association representatives. These guidelines have been published simultaneously in Diabetes Care and in Diabetologia in 2018, updated in 2019 and rewritten at the light of new evidences in 2022.

Amalia is a highly accomplished professional in the field of Biomedical Engineering and Preventive Medicine. She holds a Laurea degree in Electronic Engineering with a major in Biomedical Engineering from the University of Padova, Italy. She earned her PhD in Biomedical Engineering from Politecnico of Milano, Italy, specializing in mathematical modeling for human metabolism. Amalia also holds a second PhD in Preventive Medicine and Community Health with a major in Human Metabolism from the University of Texas Medical Branch (UTMB) in Galveston, TX, USA.

Currently, Amalia serves as the research director of the Cardio-metabolic Risk Laboratory at the Institute of Clinical Physiology of CNR in Pisa, Italy. She is also an adjunct associate professor in the Division of Diabetes at the University of Texas Health Science Center in San Antonio, TX, USA. Amalia’s contributions extend beyond her academic roles as she holds leadership positions in professional organizations. She is the Director of the European Chapter of the American College of Nutrition (ACN) and the President of the MASLD-EASD study group. She actively participates in editorial activities for renowned journals and serves as a reviewer for international publications and grants.

Her research interests revolve around glucose and lipid metabolism, insulin resistance and secretion, body fat distribution, and non-alcoholic fatty liver disease (MASLD). Her work has resulted in a significant publication record, including over 200 articles in international journals and book chapters. With her extensive expertise and collaborative efforts with institutions in Europe and the United States, Amalia continues to make valuable contributions to the field, advancing our understanding of metabolic disorders and participating in clinical trials to study the effectiveness of various medications.

William leads a thriving MRC- and Wellcome-funded research team focusing on Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) and its progressive form, Non-Alcoholic Steatohepatitis or MASH. His basic science laboratory team studies immune and metabolic signalling with current focus on multiorgan inflammation, metabolism and the bioinformatics of single cell techniques. His translational programme of research addresses MASH epidemiology and natural history, clinical care pathways including the management of abnormal liver tests and novel therapies for MASH.

William has published widely and is a reviewer and editor for leading journals and grant bodies. He has won numerous awards including the EASL Physician Scientist and a New Investigator Research Grant from the Medical Research Council. As Chair of the BSG/BASL Special Interest Group he co-led the recent production of UK Quality Standards for MASLD. He is Director of Research at the Blizard Institute, co-leads Queen Mary’s Clinical Academic Training School and NIHR Integrated Academic Training Programme and is one of the Directors of the HARP (Health Advances in Underrepresented Populations and Disease) doctoral training programme.

Mazen Noureddin, MD, MHSc, was the founding director of the Fatty Liver Program at Cedars-Sinai Medical Center and in 2022, he relocated to Houston, Texas from California to establish the state-of-the-art Houston Liver Institute.

Mazen is internationally known for his research in the area of NAFLD/NASH and NASH related cirrhosis. He conducted more than 40 investigational clinical studies of novel treatments for NASH. He is an expert in non-invasive testing and biomarkers of NASH and cirrhosis. He has published in all these areas and has been invited to consensus panels on these topics by multiple international societies including the American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of Liver Diseases (EASL). He has given invited lectures on NAFLD/NASH at national and international society meetings and serves on several steering committees/advisory boards for industry. He is the vice chair of the AASLD NASH special interest group (and chaired in 2023) and serves on the editorial board for major GI journals including “Gastroenterology”, “Hepatology” and “Clinical Gastroenterology and Hepatology (CGH)”. He is funded by the National Cancer Institute and has served as a reviewer on NIH study sections. Mazen has published in many journals including: The Lancet, Science Trinational Medicine, Journal of Hepatology, Journal of Clinical Investigation, Gastroenterology, Hepatology, Clinical Gastroenterology and Hepatology and others.

Mazen conducted his internal medicine residency at the University of Southern California (USC) before moving to the National Institutes of Health (NIH), where he enrolled in a three-year hepatology fellowship at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). There, he finished the NIH/Duke University Master of Health Sciences in Clinical Research program. After completing his NIH fellowship, he completed a gastroenterology fellowship at the University of California, San Diego (UCSD), where he was a T32 NIH fellow. He then joined the University of Southern California (USC) as an Assistant Professor of Clinical Medicine in 2013. He was then recruited to Cedars-Sinai Medical Center in 2015 to establish its new fatty liver program.

Michael joined the Metadeq Board of Directors in August 2023.  He brings more than three decades of expertise both in executive and non-executive roles in sales, marketing and general management, combined with a unique cultural perspective from living in nine different countries across Europe and the Americas.  In his last role, he served as Chief Commercial Officer at miDiagnostics and has been steering the global commercial activities of the company in the Point-Of-Care (POC) arena. Prior, Michael was President and General Manager of the International Business at Metabolon with full P&L responsibility and leading the international commercial and operational activities of the company. 

Michael also was Global Head of Sales and Business Development and later as Chief Commercial Officer at Definiens AG. Earlier in his career, at Roche Diagnostics Michael was SVP of Global Marketing for Roche’s NPT (POC) business. Michael started his carrier at Bayer Diagnostics (today Siemens Diagnostics), spending twelve years in a variety of marketing and commercial roles. 

Michael has served on several boards and has held numerous roles as an Advisor for diagnostic and life science companies. Michael holds a degree in Marketing and Finance from the private Bayer University and is a certified sales coach for the Miller Heiman sales methodology.

Mark advises diagnostic companies globally on market, product, and business development. He has 30 years of global commercial leadership in vitro diagnostics and medical device markets, supported by a technical background in chemistry and the life sciences.

Mark has served as a member of the senior staff at Waters Corporation, serving as the general manager of the company’s global clinical mass spectrometry diagnostics business unit and the senior director of business strategy and market development.  He led a cross-functional corporate initiative to bring novel, real-time anatomical pathology and tissue characterization tools to intraoperative image-guided surgical oncology, rooted in the company’s enabling technologies. Bruns also held several senior management roles at Abbott Diagnostics, managing worldwide commercial, strategy, and business development activities for its broad in vitro diagnostics portfolio. His emphasis was on market, product, and business development for Abbott’s $1.5B infectious disease diagnostics and blood banking franchises and novel biomarkers for preeclampsia and acute kidney injury.

Mark holds a Ph.D. in chemistry from the University of Illinois at Urbana-Champaign and a B.S. in chemistry from Valparaiso University.

Jeff brings 30-years of business experience to Metadeq as a proven leader with significant commercial and operations experience in the global in-vitro diagnostics (IVD) marketplace.

Jeff is the founder and managing partner at The Deerborne Group, a boutique strategy consulting firm that advises corporate, venture capital, and private equity clients operating in the global IVD marketplace.

Jeff started out his career working for Fortune 500 companies such as Abbott Diagnostics, Bayer Diagnostics, and Quest Diagnostics. In 2010, Jeff was a member of the senior executive leadership team at Clarient (Nasdaq: CLRT) when the business was acquired by GE Healthcare for $587 million. Thereafter, Jeff worked for venture-backed startup and mid-stage molecular diagnostic CLIA laboratories where he held senior executive, commercial, operational, and GM roles.

Jeff received his undergraduate degree from UCLA and is a former U.S. Navy SEAL.

Carel graduated from medical school in Pretoria South Africa, completed his specialist training in metabolic medicine at St Bartholomew’s Hospitals and the Hammersmith Hospitals. He obtained his Ph.D. from Imperial College London where he later took up a faculty position. He moved to University College Dublin for the Chair in Chemical Pathology and Metabolic Medicine and he is now a Director of the Metabolic Medicine Group. He also holds the position of Professor of Metabolic Medicine at Ulster University and Extra-ordinary Professor of Chemical Pathology at University of Pretoria. 

Carel currently coordinates an Innovative Medicine Initiative project on obesity. He previously received a President of Ireland Young Researcher Award, Irish Research Council Laurate Award, Clinician Scientist Award from the National Institute Health Research in the UK, and a Wellcome Trust Clinical Research Fellowship for his work on how the gut talks to the brain.